Clinical Trial Update: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating migalastat in Fabry disease patients with amenable GLA variants and renal disease; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• GALAFOLD (MIGALASTAT HYDROCHLORIDE)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING